modelR03BB06

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:GlycopyrroniumBromide
ATC code:R03BB06
route:inhalation
compartments:2
dosage:50mg
volume of distribution:376L
clearance:51L/h
other parameters in model implementation

Glycopyrronium bromide is a long-acting muscarinic antagonist (LAMA) used as a bronchodilator for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It acts by inhibiting acetylcholine at muscarinic receptors in the airway smooth muscle, resulting in bronchodilation. It is approved and widely used today in inhalation form for COPD.

Pharmacokinetics

Pharmacokinetic parameters obtained from healthy adult subjects following single and multiple inhaled doses of glycopyrronium bromide (in the form of glycopyrronium bromide inhalation powder 50 mcg).

References

  1. Kuna, P, et al., & Ciurlia, G (2022). Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma. Pharmacology research & perspectives 10(4) e980–None. DOI:10.1002/prp2.980 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35733414

  2. Bartels, C, et al., & Kaiser, G (2013). Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. British journal of clinical pharmacology 76(6) 868–879. DOI:10.1111/bcp.12118 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23506208

  3. Higashimori, M, et al., & Zhou, D (2021). Physiologically Based Pharmacokinetic Modelling of Glycopyrronium in Patients With Renal Impairment. Journal of pharmaceutical sciences 110(1) 438–445. DOI:10.1016/j.xphs.2020.03.014 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32240691

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)